Continued Treatment with Dupilumab is Associated with Improved Efficacy in Adults with Moderate-to-Severe Atopic Dermatitis Not Achieving Optimal Responses with Short-Term Treatment

Abstract

Introduction: Previous drug survival studies of dupilumab in atopic dermatitis (AD) show that many patients continue treatment through 1 year, suggesting that patients experience clinically relevant benefits with long-term treatment.

Methods: This post hoc analysis included data through week 100 from 391 adult patients from the dupilumab open-label extension (OLE) study who had not achieved the endpoints of at least 75% improvement from baseline in the Eczema Area and Severity Index (EASI-75) or an Investigator's Global Assessment (IGA) score of 0 or 1 with short-term (16 weeks, 300 mg qw or q2w) dupilumab treatment in the parent SOLO 1 or 2 studies. All patients received dupilumab 300 mg qw in the OLE study, irrespective of whether they received qw or 2qw dosing in the parent study.

Results: Among those who had not achieved EASI-75 or IGA 0/1 during the 16-week parent study, the proportion of patients achieving EASI-75 by week 100 was 91%. The proportion achieving IGA 0 or 1 at week 100 was 45% for patients initially on q2w week dosing and 49% for those on initial qw dosing.

Conclusion: Long-term dupilumab treatment may be associated with improvement in AD in patients with suboptimal responses during the initial 16 weeks of treatment.

Clinical trial registration: LIBERTY AD SOLO 1: ClinicalTrials.gov identifier NCT02277743; EudraCT 2014-001198-15. LIBERTY AD SOLO 2: ClinicalTrials.gov identifier NCT02277769; EudraCT 2014-002619-40.

Liberty ad ole: ClinicalTrials.gov Identifier NCT01949311; EudraCT 2013-001449-15.

Keywords: Atopic dermatitis; Dupilumab; Efficacy.

© 2021. The Author(s).

Figures

Fig. 1

Proportions of patients who achieved a EASI-75 or b an IGA score of 0 or 1 beyond week 16, but who did not achieve either of these outcomes at week 16 of SOLO 1 and 2. Treatment groups are shown by treatment allocation in the parent study (16 weeks); all patients in this analysis subsequently received 300 mg qw in the OLE study. BL baseline, EASI Eczema Area and Severity Index, EASI-75 at least 75% improvement from baseline in EASI, IGA Investigator’s Global Assessment, OLE open-label extension, q2w, every 2 weeks, qw weekly